Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia (Q38057963)

27 August 2017

title

Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia (English)

1 reference

27 August 2017

0 references

0 references

Gerhard Gross

1 reference

27 August 2017

Karsten Wicke

series ordinal

1 reference

27 August 2017

Karla U Drescher

series ordinal

1 reference

27 August 2017

publication date

6 November 2012

1 reference

Naunyn-Schmiedeberg's Archives of Pharmacology

27 August 2017

published in

1 reference

27 August 2017

volume

386

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

155-166

1 reference

Dopamine ?Autoreceptors?: Pharmacological characterization by microiontophoretic single cell recording studies

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Preclinical behavioral models for predicting antipsychotic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Does the concept of "sensitization" provide a plausible mechanism for the putative link between the environment and schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

A role for dopamine D2 receptors in reversal learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The amphetamine-induced sensitized state as a model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

A 4 Hz oscillation adaptively synchronizes prefrontal, VTA, and hippocampal activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Affinity and selectivity of [¹¹C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The preferential dopamine D3 receptor ligand, (+)-UH232, is a partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Dopamine D3 receptor antagonists as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Thinking Glutamatergically: Changing Concepts of Schizophrenia Based Upon Changing Neurochemical Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Antipsychotic Properties of the Partial Dopamine Agonist (−)-3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (Preclamol) in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The dopamine D3 receptor and drug dependence: effects on reward or beyond?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Intermediate phenotypes and genetic mechanisms of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Acute and repeated administration of the selective 5-HT(2A) receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Management of the negative symptoms of schizophrenia: new treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Identification of separable cognitive factors in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Behavioral indices in antipsychotic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

D3 dopamine receptor, behavioral sensitization, and psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Behavioural sensitization in addiction, schizophrenia, Parkinson's disease and dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The dopamine D3/D2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

D3 dopamine receptor mRNA is widely expressed in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Effects of the dopamine D3 receptor agonist, R(+)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin, on memory processes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Dopamine D1 but not D3 receptor is critical for spatial learning and related signaling in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Pramipexole as adjunct to haloperidol in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-012-0806-3

Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A

21 January 2018

1 reference

12 December 2020

S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.

1 reference

12 December 2020

Behavioral animal models to assess pro-cognitive treatments for schizophrenia

1 reference

12 December 2020

Dopamine D3 receptors expressed by all mesencephalic dopamine neurons

1 reference

12 December 2020

Dopamine D3 (auto) receptors inhibit dopamine release in the frontal cortex of freely moving rats in vivo

1 reference

12 December 2020

Imaging as tool to investigate psychoses and antipsychotics

1 reference

12 December 2020

The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro

1 reference

12 December 2020

S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic

1 reference

12 December 2020

Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs

1 reference

12 December 2020

Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?

1 reference

12 December 2020

Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex

1 reference

12 December 2020

Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction

1 reference

12 December 2020

Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor

1 reference

12 December 2020

S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626

1 reference

12 December 2020

The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats

1 reference

12 December 2020

Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits

1 reference

12 December 2020

Muscarinic mechanisms in psychotic disorders

1 reference

12 December 2020

Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities

1 reference

12 December 2020

Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity

1 reference

12 December 2020

Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo

1 reference

12 December 2020

Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats

1 reference

12 December 2020

Acute and chronic administration of the selective D(3) receptor antagonist SB-277011-A alters activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study

1 reference

12 December 2020

Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons.

1 reference

12 December 2020

Serotonergic mechanisms as targets for existing and novel antipsychotics

1 reference

12 December 2020

Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

1 reference

12 December 2020

Amisulpride: from animal pharmacology to therapeutic action

1 reference

12 December 2020

Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.

1 reference

12 December 2020

Animal Models of Schizophrenia

1 reference

12 December 2020

Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigros

1 reference

12 December 2020

The dopamine dysfunction in schizophrenia revisited: new insights into topography and course

1 reference

12 December 2020

Nicotinic receptors and functional regulation of GABA cell microcircuitry in bipolar disorder and schizophrenia

1 reference

12 December 2020

Dopamine D3 agonists disrupt social behavior in rats

1 reference

12 December 2020

Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function

1 reference

12 December 2020

Alterations in Dopamine Release But Not Dopamine Autoreceptor Function in Dopamine D3Receptor Mutant Mice

1 reference

12 December 2020

10.1007/S00210-012-0806-3

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1050414390

0 references

1 reference